Literature DB >> 1686178

The association of clinical conditions and serologic tests with CD4+ lymphocyte counts in HIV-infected subjects without AIDS.

A R Lifson1, N A Hessol, S P Buchbinder, S D Holmberg.   

Abstract

Early intervention guidelines in HIV infection require knowledge of CD4+ lymphocyte count; however, CD4+ determinations require special laboratory procedures and may not be readily available in all situations. Using data from 207 HIV-seropositive homosexual men without AIDS, we evaluated the association of difference clinical conditions or serologic tests with CD4+ count. Men with conditions including seborrheic dermatitis, hairy leukoplakia, oral candidiasis and chronic diarrhea, and men with beta2-microglobulin levels greater than or equal to 4.0 mg/l had significantly lower CD4+ counts. However, the probability that a subject with such parameters had less than 200 x 10(6)/l CD4+ cells was limited (25-63%). Although the probability that a subject with such parameters had less than 500 x 10(6)/l CD4+ cells was better (76-88%), the probability that a person without these parameters had greater than or equal to 500 x 10(6)/l CD4+ cells was only 45-50%. Clinical and serologic parameters may provide important prognostic information, but cannot be used to reliably determine the level of CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686178     DOI: 10.1097/00002030-199110000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

Review 1.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

Review 2.  The value of the CD4+ count of 500 cells/microliters.

Authors:  P Volberding
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment.

Authors:  Ditte M L Saunte; George Gaitanis; Roderick James Hay
Journal:  Front Cell Infect Microbiol       Date:  2020-03-20       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.